All In Biotech

Drug Trial Radar · NCT06530966

Phase I Study of ICP-332 in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-332 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Jul 23, 2024

Primary completion

Nov 8, 2024

Study completion Nov 8, 2024

Sponsor

Lead sponsor
InnoCare Pharma Inc.Industry
Sponsor type
Industry
First posted
Jul 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A multiple ascending dose phase I study of ICP-332 in healthy subjects

Conditions

  • Healthy Subjects

Interventions

  • ICP-332 TabletsDrug

    Eligible patients will receive ICP-332 tablets orally as per the protocol

  • ICP-332 Placebo TabletsDrug

    Eligible patients will receive ICP-332 placebo tablets orally as per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs)Time frame: Up to Day 28
  2. Number of Participants With Clinically Significant Change in Vital SignsTime frame: Up to Day 28
  3. Number of Participants With Clinically Significant Change in Electrocardiogram (ECG)Time frame: Up to Day 28
  4. Number of Participants With Clinically Significant Change in Physical ExaminationTime frame: Up to Day 28
  5. Number of Participants With Clinically Significant Change in Clinical Laboratory ValuesTime frame: Up to Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaron CPC Inc.

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.